This company has been marked as potentially delisted and may not be actively trading.

AVROBIO (AVRO) Financials

Annual Income Statements for AVROBIO

This table shows AVROBIO's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-106	-43	-58
Consolidated Net Income / (Loss)	-106	-43	-58
Net Income / (Loss) Continuing Operations	-106	-43	-58
Total Pre-Tax Income	-106	-43	-58
Total Operating Income	-105	-45	-58
Total Gross Profit	0.00	0.00	0.00
Total Revenue	0.00	0.00	0.00
Total Cost of Revenue	0.00	0.00	0.00
Total Operating Expenses	105	45	58
Selling, General & Admin Expense	33	7.68	17
Research & Development Expense	72	37	41
Total Other Income / (Expense), net	-0.46	2.08	0.03
Interest Expense	-	0.15	0.11
Interest & Investment Income	-0.30	0.58	4.26
Other Income / (Expense), net	-0.16	1.65	-4.12
Other Gains / (Losses), net	-	-	0.03
Basic Earnings per Share	($2.42)	($33.76)	($6.83)
Weighted Average Basic Shares Outstanding	43.74M	1.27M	8.49M
Diluted Earnings per Share	($2.42)	($33.76)	($6.83)
Weighted Average Diluted Shares Outstanding	43.74M	1.27M	8.49M
Weighted Average Basic & Diluted Shares Outstanding	44.09M	44.86M	18.66M
Cash Dividends to Common per Share	-	-	$0.00

This table shows AVROBIO's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-23	-25	-25	-10	-10	2.64	-6.81	-13	-18	-21
Consolidated Net Income / (Loss)	-23	-25	-25	-10	-10	2.64	-6.81	-13	-18	-21
Net Income / (Loss) Continuing Operations	-23	-25	-25	-10	-9.99	2.84	-6.81	-13	-18	-21
Total Pre-Tax Income	-23	-25	-25	-10	-10	2.90	-6.81	-13	-18	-21
Total Operating Income	-23	-25	-25	-11	-10	1.32	-7.94	-11	-20	-19
Total Operating Expenses	23	25	25	11	10	-1.32	7.94	11	20	19
Selling, General & Admin Expense	7.07	7.12	7.89	1.87	1.98	-4.05	7.26	4.35	5.32	-0.27
Research & Development Expense	16	18	17	8.77	8.13	2.73	0.68	7.07	14	19
Total Other Income / (Expense), net	0.02	0.22	0.26	0.18	0.06	1.58	1.13	-1.25	1.92	-1.77
Interest & Investment Income	0.11	0.25	0.25	0.22	0.10	0.01	1.15	0.32	1.95	0.85
Other Income / (Expense), net	-0.10	-0.02	0.02	-0.01	-0.00	1.65	-0.01	-1.54	-0.01	-2.56
Basic Earnings per Share	($0.52)	($0.57)	($0.57)	($8.51)	($7.62)	$2.08	($0.15)	($4.34)	($1.20)	($2.45)
Weighted Average Basic Shares Outstanding	43.77M	43.74M	44.04M	1.23M	1.32M	1.27M	44.79M	2.92M	14.73M	8.49M
Diluted Earnings per Share	($0.52)	($0.57)	($0.57)	($8.51)	($7.62)	$2.08	($0.15)	($4.34)	($1.20)	($2.45)
Weighted Average Diluted Shares Outstanding	43.77M	43.74M	44.04M	1.23M	1.32M	1.27M	44.79M	2.92M	14.73M	8.49M
Basic & Diluted Earnings per Share	-	($0.57)	-	-	-	$2.08	-	-	-	($2.45)
Weighted Average Basic & Diluted Shares Outstanding	43.77M	44.09M	44.11M	44.53M	44.57M	44.86M	44.89M	14.73M	14.75M	18.66M

This table details how cash moves in and out of AVROBIO's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	-97	-7.20	112
Net Cash From Operating Activities	-97	-41	-59
Net Cash From Continuing Operating Activities	-97	-41	-59
Net Income / (Loss) Continuing Operations	-106	-43	-58
Consolidated Net Income / (Loss)	-106	-43	-58
Depreciation Expense	1.44	1.48	1.65
Non-Cash Adjustments To Reconcile Net Income	15	1.25	7.54
Changes in Operating Assets and Liabilities, net	-7.40	-0.58	-10
Net Cash From Investing Activities	-0.27	-0.28	-0.16
Net Cash From Continuing Investing Activities	-0.27	-0.28	-0.16
Purchase of Property, Plant & Equipment	-0.27	-0.28	-0.16
Net Cash From Financing Activities	0.26	34	172
Net Cash From Continuing Financing Activities	0.26	34	172
Repayment of Debt	0.00	34	-0.48
Repurchase of Common Equity	-	0.00	0.00
Other Financing Activities, net	0.06	0.12	172
Effect of Exchange Rate Changes	-	0.02	-0.01
Cash Interest Paid	1.43	0.15	0.11

This table details how cash moves in and out of AVROBIO's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Change in Cash & Equivalents	-16	-24	-20	-0.80	-8.60	22	-7.54	164	-26	-18
Net Cash From Operating Activities	-16	-24	-20	-0.26	-8.48	-12	-7.57	-15	-20	-17
Net Cash From Continuing Operating Activities	-16	-24	-20	-0.26	-8.48	-12	-7.57	-15	-20	-17
Net Income / (Loss) Continuing Operations	-23	-25	-25	0.06	-10	-7.87	-6.81	-21	-18	-12
Consolidated Net Income / (Loss)	-23	-25	-25	0.06	-10	-7.87	-6.81	-21	-18	-12
Depreciation Expense	0.35	0.34	0.33	0.41	0.37	0.37	0.00	0.71	0.42	0.51
Non-Cash Adjustments To Reconcile Net Income	2.71	5.18	3.20	-2.10	0.56	-0.41	1.20	3.73	1.96	0.65
Changes in Operating Assets and Liabilities, net	3.53	-4.26	1.14	1.38	0.65	-3.75	-1.96	1.56	-4.27	-5.60
Net Cash From Investing Activities	-0.09	-	-0.01	-0.21	-0.01	-0.05	0.00	-	-0.15	-0.00
Net Cash From Continuing Investing Activities	-0.09	-	-0.01	-0.21	-0.01	-0.05	0.00	-	-0.15	-0.00
Purchase of Property, Plant & Equipment	-0.09	-	-0.01	-0.21	-0.01	-0.05	0.00	-	-0.15	-0.00
Net Cash From Financing Activities	0.06	0.06	0.06	-0.32	-0.11	34	0.03	179	-6.29	-1.07
Net Cash From Continuing Financing Activities	0.06	0.06	0.06	-0.32	-0.11	34	0.03	179	-6.29	-1.07
Repayment of Debt	-	-	-	-	-0.11	34	-	-	-0.12	-0.12
Repurchase of Common Equity	-	-	-	-	-	-	-	-	-6.24	7.41
Other Financing Activities, net	-	0.06	0.04	-0.04	-	0.12	0.03	180	0.08	-8.37
Effect of Exchange Rate Changes	-	-	-	-	-	0.02	-	-	0.02	0.04
Cash Interest Paid	0.37	0.42	0.46	-0.38	0.04	0.03	0.00	0.06	-	0.05

This table presents AVROBIO's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Total Assets	104	39	153
Total Current Assets	100	31	147
Cash & Equivalents	93	29	141
Prepaid Expenses	7.11	2.12	5.62
Plant, Property, & Equipment, net	2.89	3.12	2.15
Total Noncurrent Assets	1.10	5.39	3.90
Noncurrent Note & Lease Receivables	-	1.44	0.92
Other Noncurrent Operating Assets	1.10	3.96	2.98
Total Liabilities & Shareholders' Equity	104	39	153
Total Liabilities	29	43	12
Total Current Liabilities	13	41	12
Accounts Payable	0.38	0.41	0.98
Accrued Expenses	12	8.14	7.85
Other Current Liabilities	1.00	32	2.78
Total Noncurrent Liabilities	15	2.52	0.52
Other Noncurrent Operating Liabilities	0.19	2.52	0.52
Commitments & Contingencies	0.00	0.00	0.00
Redeemable Noncontrolling Interest	-	81	0.00
Total Equity & Noncontrolling Interests	75	-85	141
Total Preferred & Common Equity	75	-85	141
Preferred Stock	0.00	0.00	0.00
Total Common Equity	75	-85	141
Common Stock	565	5.98	289
Retained Earnings	-489	-91	-149
Accumulated Other Comprehensive Income / (Loss)	-	-0.01	0.01

This table presents AVROBIO's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024
Total Assets	129	83	134	111	92	194	169
Total Current Assets	126	77	129	109	92	187	163
Cash & Equivalents	116	72	125	106	90	185	159
Prepaid Expenses	9.77	4.93	3.87	2.86	1.07	2.26	3.50
Plant, Property, & Equipment, net	3.22	2.57	2.29	0.00	0.00	2.64	2.55
Total Noncurrent Assets	0.04	3.18	2.71	1.35	0.51	3.88	3.57
Noncurrent Note & Lease Receivables	-	-	-	-	-	2.08	1.03
Other Noncurrent Operating Assets	0.04	3.18	2.71	1.35	0.51	1.81	2.54
Total Liabilities & Shareholders' Equity	129	83	134	111	92	194	169
Total Liabilities	31	30	12	7.66	3.51	28	18
Total Current Liabilities	16	14	12	7.56	3.51	26	17
Accounts Payable	1.81	0.59	1.07	0.91	0.24	4.09	2.64
Accrued Expenses	14	11	8.34	5.00	3.04	20	13
Other Current Liabilities	-	2.63	2.25	1.65	0.22	1.90	1.95
Total Noncurrent Liabilities	15	16	0.13	0.11	0.00	1.54	1.04
Other Noncurrent Operating Liabilities	-	0.35	0.13	0.11	-	1.54	1.04
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Redeemable Noncontrolling Interest	-	-	-	-	-	0.00	0.00
Total Equity & Noncontrolling Interests	98	53	122	103	89	166	150
Total Preferred & Common Equity	98	53	122	103	89	166	150
Preferred Stock	-	-	-	-	0.00	-	0.00
Total Common Equity	98	53	122	103	89	166	150
Common Stock	562	567	569	571	573	285	287
Retained Earnings	-464	-514	-447	-468	-484	-118	-136
Accumulated Other Comprehensive Income / (Loss)	-	-	-	-	-	-0.06	-0.08

This table displays calculated financial ratios and metrics derived from AVROBIO's official financial filings.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-
Revenue Growth	0.00%	0.00%	0.00%
EBITDA Growth	11.36%	60.14%	-45.69%
EBIT Growth	11.19%	59.28%	-44.51%
NOPAT Growth	11.28%	57.65%	-29.94%
Net Income Growth	11.11%	59.56%	-35.40%
EPS Growth	12.95%	59.56%	79.77%
Operating Cash Flow Growth	0.83%	58.15%	-45.23%
Free Cash Flow Firm Growth	7.95%	99.12%	-10,694.18%
Invested Capital Growth	57.25%	-1,389.91%	98.59%
Revenue Q/Q Growth	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	2.44%	40.52%	-474.26%
EBIT Q/Q Growth	2.50%	39.64%	-500.52%
NOPAT Q/Q Growth	2.50%	37.31%	-336.69%
Net Income Q/Q Growth	2.93%	39.26%	-383.85%
EPS Q/Q Growth	2.81%	39.26%	-591.37%
Operating Cash Flow Q/Q Growth	2.24%	22.80%	22.70%
Free Cash Flow Firm Q/Q Growth	4.46%	98.64%	-422.32%
Invested Capital Q/Q Growth	30.49%	-903.31%	94.70%
Profitability Metrics	-	-	-
Gross Margin	0.00%	0.00%	0.00%
EBITDA Margin	0.00%	0.00%	0.00%
Operating Margin	0.00%	0.00%	0.00%
EBIT Margin	0.00%	0.00%	0.00%
Profit (Net Income) Margin	0.00%	0.00%	0.00%
Tax Burden Percent	100.00%	100.60%	100.00%
Interest Burden Percent	100.28%	99.00%	93.31%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%
Return on Equity (ROE)	-86.50%	-120.02%	-84.79%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%
Return on Assets (ROA)	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	-86.50%	15.58%	-34.80%
Return on Equity Simple (ROE_SIMPLE)	-140.49%	50.60%	-41.19%
Net Operating Profit after Tax (NOPAT)	-74	-31	-41
NOPAT Margin	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-25.45%	-21.76%	-20.44%
Return On Investment Capital (ROIC_SIMPLE)	-	36.93%	-28.85%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%
R&D to Revenue	0.00%	0.00%	0.00%
Operating Expenses to Revenue	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-106	-43	-62
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-104	-42	-60
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	4.97	0.00	4.84
Price to Tangible Book Value (P/TBV)	4.97	0.00	4.84
Price to Revenue (P/Rev)	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.20	0.00	0.00
Long-Term Debt to Equity	0.20	0.00	0.00
Financial Leverage	-1.03	-1.49	-1.24
Leverage Ratio	1.26	2.01	1.41
Compound Leverage Factor	1.26	1.99	1.31
Debt to Total Capital	16.85%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	16.85%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	-2,011.15%	0.00%
Common Equity to Total Capital	83.15%	2,111.15%	100.00%
Debt to EBITDA	-0.15	0.00	0.00
Net Debt to EBITDA	0.74	0.00	0.00
Long-Term Debt to EBITDA	-0.15	0.00	0.00
Debt to NOPAT	-0.21	0.00	0.00
Net Debt to NOPAT	1.05	0.00	0.00
Long-Term Debt to NOPAT	-0.21	0.00	0.00
Altman Z-Score	-1.08	2.93	32.05
Noncontrolling Interest Sharing Ratio	0.00%	112.98%	58.95%
Liquidity Ratios	-	-	-
Current Ratio	7.62	0.76	12.65
Quick Ratio	7.06	0.70	12.17
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-77	-0.68	-73
Operating Cash Flow to CapEx	-36,407.49%	-14,581.00%	-37,871.79%
Free Cash Flow to Firm to Interest Expense	0.00	-4.44	-681.55
Operating Cash Flow to Interest Expense	0.00	-267.64	-552.15
Operating Cash Flow Less CapEx to Interest Expense	0.00	-269.47	-553.61
Efficiency Ratios	-	-	-
Asset Turnover	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-
Invested Capital	-2.20	-33	-0.46
Invested Capital Turnover	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	2.95	-31	32
Enterprise Value (EV)	297	779	540
Market Capitalization	374	727	681
Book Value per Share	$1.72	($1.90)	$9.54
Tangible Book Value per Share	$1.72	($1.90)	$9.54
Total Capital	91	-4.01	141
Total Debt	15	0.00	0.00
Total Long-Term Debt	15	0.00	0.00
Net Debt	-78	-29	-141
Capital Expenditures (CapEx)	0.27	0.28	0.16
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-6.00	-39	-5.99
Debt-free Net Working Capital (DFNWC)	87	-10	135
Net Working Capital (NWC)	87	-10	135
Net Nonoperating Expense (NNE)	32	12	17
Net Nonoperating Obligations (NNO)	-78	-29	-141
Total Depreciation and Amortization (D&A)	1.44	1.48	1.65
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%
Net Working Capital to Revenue	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($29.04)	$3.24	($6.83)
Adjusted Weighted Average Basic Shares Outstanding	3.64M	3.69M	8.49M
Adjusted Diluted Earnings per Share	($29.04)	$3.24	($6.83)
Adjusted Weighted Average Diluted Shares Outstanding	3.64M	3.71M	8.49M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	3.67M	3.74M	18.66M
Normalized Net Operating Profit after Tax (NOPAT)	-74	-31	-41
Normalized NOPAT Margin	0.00%	0.00%	0.00%
Pre Tax Income Margin	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	0.00	-282.88	-580.71
NOPAT to Interest Expense	0.00	-205.62	-379.54
EBIT Less CapEx to Interest Expense	0.00	-284.71	-582.17
NOPAT Less CapEx to Interest Expense	0.00	-207.45	-381.00
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from AVROBIO's official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	29.51%	9.45%	14.41%	62.67%	57.13%	113.37%	68.03%	-19.69%	-97.25%	-731.75%
EBIT Growth	29.24%	9.66%	14.45%	61.69%	56.17%	111.72%	68.44%	-21.83%	-94.21%	-828.46%
NOPAT Growth	29.54%	9.67%	14.27%	61.72%	56.00%	107.45%	68.51%	-7.43%	-94.16%	-1,110.72%
Net Income Growth	29.57%	11.31%	16.34%	62.73%	56.23%	110.56%	72.72%	-21.20%	-76.22%	-886.45%
EPS Growth	30.67%	13.64%	16.18%	62.73%	56.23%	110.56%	73.68%	49.00%	84.25%	-217.79%
Operating Cash Flow Growth	33.87%	8.59%	27.59%	99.11%	48.33%	50.76%	62.68%	-5,724.71%	-131.15%	-44.30%
Free Cash Flow Firm Growth	22.40%	-4.35%	0.28%	86.62%	66.33%	254.64%	55.68%	325.66%	-18.65%	-243.05%
Invested Capital Growth	59.42%	57.25%	-14.14%	-382.76%	-3.22%	-1,389.91%	51.54%	-539.08%	-167.34%	98.59%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	17.10%	-9.75%	0.27%	58.87%	4.78%	134.23%	-111.54%	-53.99%	-56.92%	-9.62%
EBIT Q/Q Growth	16.89%	-9.53%	0.29%	57.79%	4.93%	129.28%	-111.54%	-62.95%	-51.56%	-9.84%
NOPAT Q/Q Growth	17.24%	-9.88%	0.15%	57.85%	4.86%	118.60%	-108.06%	-43.82%	-71.94%	3.16%
Net Income Q/Q Growth	18.13%	-8.99%	0.31%	58.11%	3.84%	126.29%	-109.85%	-86.12%	-39.82%	-17.32%
EPS Q/Q Growth	18.75%	-9.62%	0.00%	58.11%	3.84%	126.29%	-109.62%	-2,793.33%	72.35%	-104.17%
Operating Cash Flow Q/Q Growth	43.60%	-44.22%	14.32%	98.72%	-3,174.52%	-37.45%	5.75%	-99.31%	-29.95%	14.20%
Free Cash Flow Firm Q/Q Growth	20.06%	0.48%	16.79%	79.79%	-101.16%	557.09%	-107.64%	202.91%	-205.77%	-451.11%
Invested Capital Q/Q Growth	-404.91%	30.49%	-80.55%	26.11%	-11.31%	-903.31%	94.13%	-874.39%	53.44%	94.70%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBIT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Profit (Net Income) Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	91.20%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	99.52%	99.03%	99.02%	98.27%	99.40%	97.84%	85.59%	97.76%	90.19%	96.33%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-74.80%	-86.50%	-102.99%	-69.40%	-70.17%	-120.02%	42.73%	19.48%	16.13%	-84.79%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Assets (ROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	-74.80%	-86.50%	-102.99%	-69.40%	-70.17%	15.58%	42.73%	19.48%	16.13%	-34.80%
Return on Equity Simple (ROE_SIMPLE)	-111.21%	0.00%	-190.60%	-68.35%	-68.54%	0.00%	34.11%	16.88%	13.59%	0.00%
Net Operating Profit after Tax (NOPAT)	-16	-18	-18	-7.44	-7.08	1.32	-5.56	-7.99	-14	-13
NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-4.55%	-5.83%	-7.17%	-2.49%	-2.87%	2.49%	-1.69%	-3.02%	-2.99%	-8.79%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-1.56%	-	-	-	-9.46%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-23	-25	-25	-11	-10	2.96	-7.95	-13	-20	-22
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-23	-25	-25	-10	-9.74	3.34	-7.95	-12	-19	-21
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	3.44	4.97	9.98	4.12	8.00	0.00	7.76	0.37	2.97	4.84
Price to Tangible Book Value (P/TBV)	3.44	4.97	9.98	4.12	8.00	0.00	7.76	0.37	2.97	4.84
Price to Revenue (P/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	22.74	2.19	21.86	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	4.40%	45.59%	4.58%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	21.64	0.00	17.78	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	21.86	0.00	18.52	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	21.78	0.00	16.75	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	23.53	0.00	12.70	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.16	0.20	0.29	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.16	0.20	0.29	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.04	-1.03	-1.04	-1.01	-1.03	-1.49	-1.04	-1.08	-1.05	-1.24
Leverage Ratio	1.19	1.26	1.32	1.17	1.19	2.01	1.24	1.14	1.10	1.41
Compound Leverage Factor	1.18	1.24	1.30	1.15	1.19	1.97	1.06	1.11	0.99	1.35
Debt to Total Capital	13.42%	16.85%	22.47%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	13.42%	16.85%	22.47%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	-2,011.15%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	86.58%	83.15%	77.53%	100.00%	100.00%	2,111.15%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	-0.14	-0.15	-0.15	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.95	0.74	0.57	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	-0.14	-0.15	-0.15	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	-0.20	-0.21	-0.22	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	1.34	1.05	0.80	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	-0.20	-0.21	-0.22	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	1.86	1.47	1.81	21.69	59.29	6.78	111.35	1.26	14.11	32.93
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	112.98%	0.00%	0.00%	0.00%	58.95%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	7.80	7.62	5.40	11.05	14.44	0.76	26.17	7.21	9.39	12.65
Quick Ratio	7.16	7.06	5.06	10.69	14.00	0.70	25.79	7.12	9.19	12.17
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-21	-21	-17	-3.47	-6.98	32	-7.61	7.83	-8.28	-46
Operating Cash Flow to CapEx	-19,087.21%	0.00%	-253,550.00%	-121.03%	-121,157.14%	-23,314.00%	0.00%	0.00%	-12,813.07%	-560,700.00%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	-86.72	-193.83	0.00	0.00	279.55	-331.16	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	-6.48	-235.58	0.00	0.00	-538.79	-784.16	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	-11.83	-235.78	0.00	0.00	-538.79	-790.28	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-3.17	-2.20	-3.97	-2.94	-3.27	-33	-1.93	-19	-8.73	-0.46
Invested Capital Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	4.64	2.95	-0.49	-3.97	-0.10	-31	2.05	-16	-5.47	32
Enterprise Value (EV)	236	297	472	378	717	779	598	-124	287	540
Market Capitalization	337	374	529	503	823	727	689	62	446	681
Book Value per Share	$2.24	$1.72	$1.20	$2.77	$2.31	($1.90)	$1.98	$3.71	$10.20	$9.54
Tangible Book Value per Share	$2.24	$1.72	$1.20	$2.77	$2.31	($1.90)	$1.98	$3.71	$10.20	$9.54
Total Capital	113	91	68	122	103	-4.01	89	166	150	141
Total Debt	15	15	15	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	15	15	15	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-101	-78	-57	-125	-106	-29	-91	-185	-159	-141
Capital Expenditures (CapEx)	0.09	0.00	0.01	0.21	0.01	0.05	0.00	0.00	0.15	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-6.42	-6.00	-9.37	-7.79	-4.51	-39	-2.44	-24	-14	-5.99
Debt-free Net Working Capital (DFNWC)	110	87	63	117	102	-10	88	161	145	135
Net Working Capital (NWC)	110	87	63	117	102	-10	88	161	145	135
Net Nonoperating Expense (NNE)	6.88	7.35	7.30	3.01	2.97	-1.33	1.25	4.68	3.97	7.47
Net Nonoperating Obligations (NNO)	-101	-78	-57	-125	-106	-29	-91	-185	-159	-141
Total Depreciation and Amortization (D&A)	0.35	0.34	0.33	0.41	0.37	0.37	0.00	0.71	0.42	0.51
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($6.24)	($6.84)	($6.84)	$18.36	($5.76)	$24.96	($1.80)	($4.34)	($1.20)	($2.45)
Adjusted Weighted Average Basic Shares Outstanding	3.65M	3.64M	3.67M	3.68M	3.71M	105.71K	3.73M	2.92M	14.73M	8.49M
Adjusted Diluted Earnings per Share	($6.24)	($6.84)	($6.84)	$18.24	($5.76)	$24.96	($1.80)	($4.34)	($1.20)	($2.45)
Adjusted Weighted Average Diluted Shares Outstanding	3.65M	3.64M	3.67M	3.69M	3.71M	105.71K	3.73M	2.92M	14.73M	8.49M
Adjusted Basic & Diluted Earnings per Share	$0.00	($6.84)	$0.00	$0.00	$0.00	$24.96	$0.00	$0.00	$0.00	($2.45)
Adjusted Weighted Average Basic & Diluted Shares Outstanding	3.65M	3.67M	3.68M	3.71M	3.71M	3.74M	3.74M	14.73M	14.75M	18.66M
Normalized Net Operating Profit after Tax (NOPAT)	-16	-18	-18	-7.44	-7.08	0.92	-5.56	-7.99	-14	-13
Normalized NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Pre Tax Income Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	-265.98	-280.97	0.00	0.00	-462.89	-785.76	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	-186.04	-196.66	0.00	0.00	-285.53	-549.84	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	-271.33	-281.17	0.00	0.00	-462.89	-791.88	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	-191.39	-196.86	0.00	0.00	-285.53	-555.96	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About AVROBIO's Financials

When does AVROBIO's fiscal year end?

According to the most recent income statement we have on file, AVROBIO's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has AVROBIO's net income changed over the last 2 years?

AVROBIO's net income appears to be on a downward trend, with a most recent value of -$57.98 million in 2024, falling from -$105.89 million in 2022. The previous period was -$42.82 million in 2023.

What is AVROBIO's operating income?

AVROBIO's total operating income in 2024 was -$58.02 million, based on the following breakdown:

Total Gross Profit: $0.00
Total Operating Expenses: $58.02 million

How has AVROBIO revenue changed over the last 2 years?

Over the last 2 years, AVROBIO's total revenue changed from $0.00 in 2022 to $0.00 in 2024, a change of 0.0%.

How much debt does AVROBIO have?

AVROBIO's total liabilities were at $12.13 million at the end of 2024, a 72.1% decrease from 2023, and a 57.6% decrease since 2022.

How much cash does AVROBIO have?

In the past 2 years, AVROBIO's cash and equivalents has ranged from $28.77 million in 2023 to $141.24 million in 2024, and is currently $141.24 million as of their latest financial filing in 2024.

How has AVROBIO's book value per share changed over the last 2 years?

Over the last 2 years, AVROBIO's book value per share changed from 1.72 in 2022 to 9.54 in 2024, a change of 454.2%.

This page (NASDAQ:AVRO) was last updated on 5/10/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AVROBIO (AVRO) Financials

Frequently Asked Questions About AVROBIO's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AVROBIO (AVRO) Financials

Annual Income Statements for AVROBIO

Quarterly Income Statements for AVROBIO

Annual Cash Flow Statements for AVROBIO

Quarterly Cash Flow Statements for AVROBIO

Annual Balance Sheets for AVROBIO

Quarterly Balance Sheets for AVROBIO

Annual Metrics and Ratios for AVROBIO

Quarterly Metrics and Ratios for AVROBIO

Frequently Asked Questions About AVROBIO's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools